Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M{DMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L3emlEPTB;MD6wOlEh|ryP MkXhV2FPT0WU
ALL-PO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorITWM2OD1yLkC2N|U2KM7:TR?= MXXTRW5ITVJ?
697 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HzNGlEPTB;MD6wPVk4PiEQvF2= M4iwRnNCVkeHUh?=
NCI-H748 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVftVFQ5UUN3ME2wMlExOzN2IN88US=> M3jKdHNCVkeHUh?=
NKM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTzcm12UUN3ME2wMlExQTF{IN88US=> NIGyNFVUSU6JRWK=
ES1 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DoWmlEPTB;MD6xNVI2PSEQvF2= M17G[XNCVkeHUh?=
NCI-H1963 NV\JbVdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S2eGlEPTB;MD6xNVU4QSEQvF2= MlzwV2FPT0WU
NCI-H1417 NES3eG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XndmlEPTB;MD6xNlk4PCEQvF2= MmnNV2FPT0WU
NEC8 NUXWSnhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGzTWM2OD1yLkGzOVI4KM7:TR?= MkHXV2FPT0WU
CRO-AP2 M1rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMU[4PFkh|ryP NVrrSlRHW0GQR1XS
A3-KAW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mxdmlEPTB;MD6xO|YzPyEQvF2= MUjTRW5ITVJ?
SF539 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD1yLkG5OVk{KM7:TR?= M4fuZXNCVkeHUh?=
NOS-1 M2POeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\6TWM2OD1yLkG5OlE6KM7:TR?= NHzSb2RUSU6JRWK=
NTERA-S-cl-D1 M{DtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfacWdGUUN3ME2wMlIxOTF|IN88US=> MXPTRW5ITVJ?
COR-L88 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDWGlEPTB;MD6yNlk2QSEQvF2= NUXCPZN4W0GQR1XS
EM-2 NHTWbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPzdHZbUUN3ME2wMlI1ODd7IN88US=> MYXTRW5ITVJ?
KARPAS-45 M3zMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO5NGFKSzVyPUCuNlc5OzNizszN NGTpeY9USU6JRWK=
DSH1 NF63O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;4c2lEPTB;MD6yPFcxQCEQvF2= MYLTRW5ITVJ?
HT-144 NIfUeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37oO2lEPTB;MD6zNFI2PiEQvF2= MUXTRW5ITVJ?
ATN-1 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\r[YxKSzVyPUCuN|A2PzZizszN M13BeHNCVkeHUh?=
HEL MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofGTWM2OD1yLkOxN|Q5KM7:TR?= NEC4OIVUSU6JRWK=
NB12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPxelhtUUN3ME2wMlMyPzV4IN88US=> MUDTRW5ITVJ?
LU-139 NVPFc2VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{O1NUDPxE1? NU\GTJEzW0GQR1XS
J-RT3-T3-5 NH7ZXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHMeo8yUUN3ME2wMlM{PzF4IN88US=> MW\TRW5ITVJ?
MOLT-13 M3\Qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwM{O4NUDPxE1? MUXTRW5ITVJ?
SR M2PNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwM{SyOlEh|ryP NVTIVI97W0GQR1XS
CMK M3HkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TPWWlEPTB;MD6zOVczPyEQvF2= NWLxR4M2W0GQR1XS
ES8 M3zH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojWTWM2OD1yLkO2NFIzKM7:TR?= NGDPeJpUSU6JRWK=
LB647-SCLC NWHYcGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLsTWM2OD1yLkO2O|Mh|ryP NWTxNm5rW0GQR1XS
TE-8 NV;PdXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD1yLkO2PVM2KM7:TR?= NV\pWZZXW0GQR1XS
BV-173 NWiyXHZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwM{exNlEh|ryP MWTTRW5ITVJ?
DEL NYDrVHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfx[nlKSzVyPUCuN|c1QDdizszN MoXJV2FPT0WU
ARH-77 NV6zT5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PCTmlEPTB;MD6zPFE6OyEQvF2= MlH2V2FPT0WU
NCCIT NEjDV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jKe2lEPTB;MD6zPFY1QSEQvF2= NXTyN4hHW0GQR1XS
RPMI-8402 NFTkdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknRTWM2OD1yLkO4O|AyKM7:TR?= MkLLV2FPT0WU
MONO-MAC-6 M4HlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn3SmRKSzVyPUCuN|g4PzZizszN MVnTRW5ITVJ?
SK-MM-2 NVzHXWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LiXWlEPTB;MD6zPVg3QCEQvF2= Mnv0V2FPT0WU
CHP-126 NVW2Zm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj2TWM2OD1yLkSwNlMyKM7:TR?= MXnTRW5ITVJ?
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\ER|JKSzVyPUCuOFA{KM7:TR?= MVvTRW5ITVJ?
SCH NVrPSZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzTOXIzUUN3ME2wMlQxOzR{IN88US=> M1r5b3NCVkeHUh?=
NMC-G1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nON2lEPTB;MD60NFM3PyEQvF2= M4DTUXNCVkeHUh?=
NCI-H209 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j4VWlEPTB;MD60NFYyOyEQvF2= NH7GNmdUSU6JRWK=
MOLT-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTC[|hKSzVyPUCuOFExOTdizszN NUHSO3htW0GQR1XS
RPMI-6666 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HyVGlEPTB;MD60NVEzKM7:TR?= MoL2V2FPT0WU
OPM-2 NFPvWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzW4k4UUN3ME2wMlQyPTF|IN88US=> NWTkcllbW0GQR1XS
MRK-nu-1 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\LOGo4UUN3ME2wMlQ{OTV|IN88US=> MVTTRW5ITVJ?
BC-1 NX[zUHZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnYZ2pKSzVyPUCuOFM1ODNizszN NXjoXIU1W0GQR1XS
MHH-NB-11 NXjZe3kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNEO0OVMh|ryP NWHuW3NIW0GQR1XS
Ramos-2G6-4C10 NFX2R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDVT5hKUUN3ME2wMlQ{QDl5IN88US=> MWnTRW5ITVJ?
LS-513 M33ZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvlT2tKSzVyPUCuOFQ2ODFizszN MmXWV2FPT0WU
K5 M3XlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD3SodzUUN3ME2wMlQ4ODJ3IN88US=> NWfnbphMW0GQR1XS
HOP-62 M3zYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHZeG9KSzVyPUCuOFg{PThizszN M{DyOnNCVkeHUh?=
NCI-H187 NH:zb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNEmyNlch|ryP MXfTRW5ITVJ?
BE-13 NWHUN|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKxTIdKSzVyPUCuOFk3PjFizszN NFnWNppUSU6JRWK=
HC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn62TWM2OD1yLkWwOFc{KM7:TR?= NY\DUWJEW0GQR1XS
ACN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\XeWlEPTB;MD61NVAzQCEQvF2= M{P2OnNCVkeHUh?=
HCC1599 NH7GcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTsfohKSzVyPUCuOVE2PyEQvF2= NHX2dndUSU6JRWK=
MV-4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOwUXVKSzVyPUCuOVMxPDFizszN MXvTRW5ITVJ?
LC-2-ad NVXZNW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzoTWM2OD1yLkWzOlY{KM7:TR?= M1rPc3NCVkeHUh?=
HL-60 NEi2NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzkO2ZoUUN3ME2wMlU1OjZzIN88US=> NXnWXolsW0GQR1XS
NB17 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDkfHpKSzVyPUCuOVQ{QCEQvF2= M3fvZXNCVkeHUh?=
TE-1 NF;zNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvlRWNKSzVyPUCuOVU{ODZizszN NHu0Z3pUSU6JRWK=
NCI-H524 NEm5b5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPITnh2UUN3ME2wMlU2PDBzIN88US=> NYPDcGJjW0GQR1XS
MZ7-mel MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nRSGlEPTB;MD61OlExPSEQvF2= MnnYV2FPT0WU
L-363 NHj3RWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YTWM2OD1yLkW2OlU4KM7:TR?= MV;TRW5ITVJ?
BL-41 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP3ZmdKSzVyPUCuOVY5QDlizszN MnPWV2FPT0WU
LU-134-A NYG5PJZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfuWo5tUUN3ME2wMlU4ODd|IN88US=> M2Hn[3NCVkeHUh?=
SIG-M5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ydmlEPTB;MD61O|g1QCEQvF2= NY\ISXlmW0GQR1XS
ONS-76 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7JTWM2OD1yLkW4NlQzKM7:TR?= NEfpfGJUSU6JRWK=
KARPAS-299 M1fMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\iPVBKSzVyPUCuOVg2ODRizszN MW\TRW5ITVJ?
DU-4475 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HPdGlEPTB;MD61PFcxOyEQvF2= NUfrd|ZCW0GQR1XS
NB69 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwNUm4NlUh|ryP NWDlR|VvW0GQR1XS
MHH-PREB-1 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nzN2lEPTB;MD62NFcyQSEQvF2= MX3TRW5ITVJ?
LU-165 NYizSG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzW2lEPTB;MD62NVgyOiEQvF2= MXrTRW5ITVJ?
LOUCY MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTIVXFlUUN3ME2wMlY{OzZ2IN88US=> NFvkeIpUSU6JRWK=
NCI-H526 NHnv[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnIe241UUN3ME2wMlY{PTRzIN88US=> NEnhc2FUSU6JRWK=
KE-37 M3zOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwNYpKSzVyPUCuOlQzPzZizszN M1i3e3NCVkeHUh?=
NALM-6 NHzRcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\w[mlEPTB;MD62OFg3KM7:TR?= NVvjdnVbW0GQR1XS
CW-2 M2f6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fWNWlEPTB;MD62OVc6PCEQvF2= M2LLWnNCVkeHUh?=
SU-DHL-1 NVnOSHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0dFBHUUN3ME2wMlY2QTR5IN88US=> M2LQWXNCVkeHUh?=
NB13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNk[4NVch|ryP MmTjV2FPT0WU
QIMR-WIL NXvKOZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNkizOFMh|ryP MlL4V2FPT0WU
ECC12 M1yxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwN{CwPFYh|ryP NWD5c2pNW0GQR1XS
KALS-1 NEPTWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vSNWlEPTB;MD63NFQ6OiEQvF2= NXrDc496W0GQR1XS
COR-L279 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwN{C5PVYh|ryP NYW2NJhNW0GQR1XS
NB14 NWfPSIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH22WZNKSzVyPUCuO|I3OTdizszN M1LHZXNCVkeHUh?=
CCRF-CEM NYf0XVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ixPGlEPTB;MD63OFY3OSEQvF2= MV7TRW5ITVJ?
SW954 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLFTWM2OD1yLke1PVk6KM7:TR?= MljBV2FPT0WU
IST-SL1 NYX6bpZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS2eJk6UUN3ME2wMlc4OzR6IN88US=> NG\1TlBUSU6JRWK=
LAMA-84 NEjj[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\STWM2OD1yLke3OVY4KM7:TR?= NF;GV2tUSU6JRWK=
Daudi NFK2b3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmzVI9KSzVyPUCuO|c3QDFizszN NVH0RoJqW0GQR1XS
BC-3 NYrIZVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrMbI02UUN3ME2wMlc5OzB6IN88US=> M3jPWHNCVkeHUh?=
HCC2998 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv1TWM2OD1yLke4N|Yh|ryP MWPTRW5ITVJ?
NCI-H69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;tSlc1UUN3ME2wMlgxOTR5IN88US=> M1G0VHNCVkeHUh?=
CPC-N NW\iWZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfPWIRKSzVyPUCuPFA2OjRizszN M{HtOHNCVkeHUh?=
NOMO-1 NGTueVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITpPY5KSzVyPUCuPFExQDRizszN NWPDbIo2W0GQR1XS
CESS M1X4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmxT3pPUUN3ME2wMlgyOTl5IN88US=> NFPm[5lUSU6JRWK=
LC4-1 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD5TWM2OD1yLki0NFA4KM7:TR?= MlG5V2FPT0WU
BL-70 M1zndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWzU4VKSzVyPUCuPFU4ODJizszN NEjkOmRUSU6JRWK=
ES4 M4S4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzuZlBnUUN3ME2wMlg2QDZ6IN88US=> M3nIWXNCVkeHUh?=
HCE-T MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PXVmlEPTB;MD64O|E4OSEQvF2= MUXTRW5ITVJ?
JAR NE\X[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTNS|BKSzVyPUCuPFc5OjdizszN NGHDNIVUSU6JRWK=
ST486 NHzwTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPFfmxKSzVyPUCuPFc6OTdizszN MUnTRW5ITVJ?
KS-1 NX;zeYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPVXZZ3UUN3ME2wMlg5ODl4IN88US=> MULTRW5ITVJ?
GDM-1 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwOEi2PFch|ryP NUTOVGI{W0GQR1XS
EHEB NXLpU|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwOUK1PFUh|ryP M3vNdXNCVkeHUh?=
LB2518-MEL M{ftfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDPU|FKSzVyPUCuPVMzQDRizszN NUj5SGttW0GQR1XS
GOTO MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrQS5lKSzVyPUCuPVUxPzZizszN M2LsUXNCVkeHUh?=
LXF-289 M3nYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPDNnFYUUN3ME2wMlk2QTBzIN88US=> MWPTRW5ITVJ?
ES6 NGPmOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtb4hKSzVyPUCuPVY1OzdizszN MorFV2FPT0WU
OS-RC-2 M3\1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2yUodKSzVyPUCuPVY5OyEQvF2= NHjHeVhUSU6JRWK=
DMS-153 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDEO3hKSzVyPUCuPVc1PjlizszN M4rtVXNCVkeHUh?=
SK-PN-DW NH:wUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj1TWM2OD1yLkm3PFMyKM7:TR?= MVfTRW5ITVJ?
HH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nlZ2lEPTB;MD65PFk2QSEQvF2= NXTSRZNVW0GQR1XS
SH-4 NE\KdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HPZWlEPTB;MT6wNlQyKM7:TR?= MkDuV2FPT0WU
MOLT-4 NHy1Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXmNJZQUUN3ME2xMlA{PDV2IN88US=> MV;TRW5ITVJ?
TGW M2TBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXlTWM2OD1zLkC3Olc2KM7:TR?= NX\PO|B1W0GQR1XS
L-540 M3PzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwMUC2NFQh|ryP MVrTRW5ITVJ?
PF-382 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsboRKSzVyPUGuNVE2OTNizszN NUH1WlZqW0GQR1XS
LC-1F MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2zZWlKSzVyPUGuNVIxODdizszN M1LS[nNCVkeHUh?=
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD1zLkGzNVY2KM7:TR?= NFr0bGZUSU6JRWK=
A4-Fuk Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PhV2lEPTB;MT6xOVM3PCEQvF2= MnfsV2FPT0WU
HCC2218 NI\5[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoizTWM2OD1zLkG2OlQyKM7:TR?= NIPCR41USU6JRWK=
HAL-01 NGnwRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD1zLkG2PVQ{KM7:TR?= NGThWG5USU6JRWK=
IST-MEL1 NHG5bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMUe2OVkh|ryP NGT4VI5USU6JRWK=
NCI-H719 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yO2lEPTB;MT6xO|g6QCEQvF2= MUTTRW5ITVJ?
EVSA-T NUW3V3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon2TWM2OD1zLkG4NVE1KM7:TR?= M3u0SHNCVkeHUh?=
SK-NEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzTOmxOUUN3ME2xMlIxOjZ4IN88US=> MnrrV2FPT0WU
OCUB-M NHzzd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULH[JhFUUN3ME2xMlIyPDh7IN88US=> MknMV2FPT0WU
MEG-01 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwcoJKSzVyPUGuNlIyOThizszN Mlj0V2FPT0WU
no-10 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnhfJpKSzVyPUGuNlMyOTJizszN M{S0SHNCVkeHUh?=
MHH-CALL-2 NGPCXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX0VY5KSzVyPUGuNlQ4OjFizszN MoXvV2FPT0WU
SK-N-DZ NF7rc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfGeItKSzVyPUGuNlQ4PzZizszN MU\TRW5ITVJ?
SCLC-21H MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SyU2lEPTB;MT6yOlQ4QCEQvF2= MWLTRW5ITVJ?
CTV-1 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WyVmlEPTB;MT6yO|QzPSEQvF2= NFjJV4tUSU6JRWK=
NB1 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwMke3N|Ih|ryP M4rQeXNCVkeHUh?=
NCI-H64 NULJUFE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDYRm41UUN3ME2xMlI5PDZ{IN88US=> MYHTRW5ITVJ?
MDA-MB-134-VI MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDTXYhKSzVyPUGuNlg2PzdizszN MY\TRW5ITVJ?
LB2241-RCC NXfQfWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvpb|ZKSzVyPUGuNlg3PjNizszN M2HlVHNCVkeHUh?=
8-MG-BA M{XEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXJV5R7UUN3ME2xMlI5QDZ4IN88US=> M2jjeXNCVkeHUh?=
LP-1 NVTDTW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMkm5OFch|ryP NUDIN4E3W0GQR1XS
LS-411N NE\GfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi3[4dSUUN3ME2xMlMxQTl6IN88US=> NVHwWWFoW0GQR1XS
CAL-148 M2jZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmixTWM2OD1zLkOyOVQzKM7:TR?= MXfTRW5ITVJ?
NCI-H2171 NVm1d|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zpRWlEPTB;MT6zOFUxOiEQvF2= M{f3d3NCVkeHUh?=
JiyoyeP-2003 NIPCNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rwcGlEPTB;MT6zOVM6KM7:TR?= MUjTRW5ITVJ?
NCI-H2107 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHGV4d{UUN3ME2xMlM2QDh|IN88US=> MYDTRW5ITVJ?
BB30-HNC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjKUWlKSzVyPUGuN|g6PzhizszN MonLV2FPT0WU
K-562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnJTWM2OD1zLkO5NlE6KM7:TR?= NGPybYxUSU6JRWK=
PSN1 M3eySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLlWYxKSzVyPUGuOFIzQDdizszN NVnQdWtOW0GQR1XS
HCC2157 NUPIXogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrGTWM2OD1zLkSyOlkyKM7:TR?= MWTTRW5ITVJ?
SBC-1 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ZXYdKSzVyPUGuOFI4PDFizszN Ml;RV2FPT0WU
MC116 NFzoUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwNEO2NVUh|ryP NGDFeYZUSU6JRWK=
KARPAS-422 NUnrfphzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLfZVIUUN3ME2xMlQ2OzV6IN88US=> NXn2bYljW0GQR1XS
LB996-RCC NHO0bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPNcVdIUUN3ME2xMlQ4OTB|IN88US=> MnjjV2FPT0WU
MSTO-211H MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwNEe5PFch|ryP NHLOZVVUSU6JRWK=
BT-474 M2TKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPPTWM2OD1zLkWxO|Y1KM7:TR?= NY\wOo1WW0GQR1XS
A388 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXzXJV[UUN3ME2xMlUyQTR3IN88US=> M4jycnNCVkeHUh?=
SJSA-1 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ud3poUUN3ME2xMlUzOjZizszN NILTU49USU6JRWK=
COLO-829 NIryRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\0TWM2OD1zLkWzOVY1KM7:TR?= MlfoV2FPT0WU
KM-H2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTU2lEPTB;MT61OlY4KM7:TR?= NX3LdJRuW0GQR1XS
GR-ST NYDzPIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHqWXhKSzVyPUGuOVY5OiEQvF2= NELzemNUSU6JRWK=
RPMI-8866 NWDPcVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzqTIFxUUN3ME2xMlYxOTR2IN88US=> MXHTRW5ITVJ?
KG-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjKNHFKSzVyPUGuOlE6ODFizszN MXnTRW5ITVJ?
NCI-H82 NFPiTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj4OnFOUUN3ME2xMlY{PDB4IN88US=> NXrhV49HW0GQR1XS
LB1047-RCC M2XR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHsRYtzUUN3ME2xMlY{PDV7IN88US=> MnzTV2FPT0WU
KM12 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD1zLk[0O{DPxE1? MXHTRW5ITVJ?
NB5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILHbYFKSzVyPUGuOlU3PzdizszN NEXpZ5RUSU6JRWK=
HDLM-2 M1nV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:3TWM2OD1zLk[4NlgyKM7:TR?= MlvtV2FPT0WU
KU812 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfWWJJKSzVyPUGuOlk3ODVizszN MkTyV2FPT0WU
DB NYfLemd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXjRWlJUUN3ME2xMlcxOzV|IN88US=> NI\PWFhUSU6JRWK=
HD-MY-Z NIC0N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHaeWVKSzVyPUGuO|UzOzRizszN NXO5R5NyW0GQR1XS
KURAMOCHI MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwN{eyNFch|ryP M1zZfnNCVkeHUh?=
ETK-1 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjV[|hKSzVyPUGuO|g5PzlizszN MXTTRW5ITVJ?
SK-UT-1 NUPYPI1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;hWG9LUUN3ME2xMlc6Ozh6IN88US=> MmnZV2FPT0WU
HUTU-80 NGO0XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6c5R2UUN3ME2xMlc6PTB6IN88US=> Mlm4V2FPT0WU
ES7 NWnjc3duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz5TWM2OD1zLkiwN|AzKM7:TR?= M2XFTnNCVkeHUh?=
SW872 NXPPT5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvT2lEPTB;MT64NVM6PSEQvF2= NH\HcllUSU6JRWK=
TK10 NIfDcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu5d3hzUUN3ME2xMlg{OTB6IN88US=> M3LTXXNCVkeHUh?=
LB831-BLC M33Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwOEO1OlMh|ryP MUnTRW5ITVJ?
TE-9 NU\UOHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PGfGlEPTB;MT64OFQzOiEQvF2= M4POZXNCVkeHUh?=
MLMA MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwOEiyN|Qh|ryP MkfIV2FPT0WU
D-542MG M3:3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHRbJh6UUN3ME2xMlg6Ozd|IN88US=> M2L6O3NCVkeHUh?=
EW-16 NVTpPWlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfkU2hoUUN3ME2xMlkzPzJizszN NVLTPI5sW0GQR1XS
LOXIMVI NGixR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHnd2RKSzVyPUGuPVMzQCEQvF2= MlLwV2FPT0WU
GB-1 NFzOe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TxXWlEPTB;MT65N|g3PiEQvF2= MljZV2FPT0WU
IST-SL2 NVnUbGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnFVIdKSzVyPUKuNFAzPjJizszN NW\SO|NEW0GQR1XS
LAN-6 NF;pcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtZoZKSzVyPUKuNFE6PjZizszN MX;TRW5ITVJ?
NCI-H510A MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3eGlEPTB;Mj6wOFUxOiEQvF2= MW\TRW5ITVJ?
NCI-H1092 NHS0S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ftfGlEPTB;Mj6wOVEzPCEQvF2= NFHKSmJUSU6JRWK=
HT NXrVS2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrvSGRKSzVyPUKuNVA1PTRizszN NGrFemNUSU6JRWK=
RL95-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlVWsyUUN3ME2yMlEyPDh{IN88US=> MkDOV2FPT0WU
NCI-H1355 NEX4fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwMUG3PVIh|ryP MmnjV2FPT0WU
NCI-H720 NInoT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTsXoxnUUN3ME2yMlE3QDd|IN88US=> M1rySHNCVkeHUh?=
NCI-H1522 NHmwflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwMkG3NlMh|ryP MnO5V2FPT0WU
LB373-MEL-D NX;yNJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[3cmlEPTB;Mj6yOlkxOiEQvF2= NEixb4tUSU6JRWK=
DG-75 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j4PWlEPTB;Mj6yO|E1QCEQvF2= MlvpV2FPT0WU
ML-2 NGDDW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3WZWlHUUN3ME2yMlMzQDV3IN88US=> NIPYRpVUSU6JRWK=
SF126 M{PxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLCZ4h3UUN3ME2yMlM{ODl2IN88US=> NIn2cXpUSU6JRWK=
MPP-89 NFHyXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDU|hKSzVyPUKuN|MyPDVizszN NWPTOZdQW0GQR1XS
NCI-H345 NFvHSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rxb2lEPTB;Mj6zN|I4PyEQvF2= M1j4WHNCVkeHUh?=
LS-123 NIH5N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxcGlEPTB;Mj6zOFk{PiEQvF2= NGTO[pNUSU6JRWK=
NB10 NGLCZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHhNpNZUUN3ME2yMlQyODl{IN88US=> MWLTRW5ITVJ?
CGTH-W-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwNEKyOlch|ryP MV7TRW5ITVJ?
CP66-MEL NXLLS|NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfhcJNkUUN3ME2yMlQ4PzdizszN MX3TRW5ITVJ?
L-428 NUnPN|I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXwS29KSzVyPUKuOFg2OjFizszN NXXncI5kW0GQR1XS
DMS-79 NF3MR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC1d2FFUUN3ME2yMlU1OTB|IN88US=> NHrmU2FUSU6JRWK=
NCI-H1882 NF\mfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHLTWM2OD1{Lk[3OVYzKM7:TR?= MXvTRW5ITVJ?
KGN NGLKcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPjWocxUUN3ME2yMlc3QDd4IN88US=> MkexV2FPT0WU
EW-1 NGq0ZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwN{ewPFMh|ryP MkezV2FPT0WU
U-266 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJwOES4NlMh|ryP NEjsXXJUSU6JRWK=
COLO-320-HSR M3\Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJwOEW2OFEh|ryP NGOyNnNUSU6JRWK=
KMOE-2 NXG3U4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3d2lEPTB;Mj64O|cyOSEQvF2= M1zySnNCVkeHUh?=
BB49-HNC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwOUK0PEDPxE1? NFP6NVJUSU6JRWK=
GI-1 NF\rRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfhTWM2OD1{LkmyPVU4KM7:TR?= MWnTRW5ITVJ?
NCI-H1304 M4DUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwMEC1NVEh|ryP NYDXfJBrW0GQR1XS
NCI-H2227 NVfIc2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwMEKwO|kh|ryP Ml3BV2FPT0WU
U-87-MG NY[3TolGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;6fIJKSzVyPUOuNFM2OTNizszN MkXjV2FPT0WU
NCI-H747 NVTy[pk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwMEWyNFYh|ryP NILVTXhUSU6JRWK=
CTB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwMEWzO|Yh|ryP MlKxV2FPT0WU
RPMI-8226 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jscmlEPTB;Mz6xOFM4QCEQvF2= M2D1OnNCVkeHUh?=
NCI-H2141 NYXYUllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXwU49uUUN3ME2zMlE3PTZ4IN88US=> MW\TRW5ITVJ?
IST-MES1 M{jnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:wT4g3UUN3ME2zMlE5Ojd7IN88US=> M3Hz[HNCVkeHUh?=
TE-5 M{ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7qcplWUUN3ME2zMlIyOzR{IN88US=> MknIV2FPT0WU
UACC-257 M3XibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj2S2FGUUN3ME2zMlQ{PjV7IN88US=> Ml3HV2FPT0WU
SK-N-FI NVrGWpBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknMTWM2OD1|LkS1NlI4KM7:TR?= NFzQVIJUSU6JRWK=
MFH-ino MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zLbWlEPTB;Mz60OlU5QSEQvF2= NFzEd2RUSU6JRWK=
SF268 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfGZZRKSzVyPUOuOFgyPzRizszN M1\LWnNCVkeHUh?=
TE-12 NUXqZ3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;3TWM2OD1|LkWxOlk6KM7:TR?= MU\TRW5ITVJ?
NB6 M3Hucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT4fHJKSzVyPUOuOVU2PjNizszN NHXySIhUSU6JRWK=
DJM-1 NEnhZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L4VGlEPTB;Mz61PVg6QSEQvF2= Ml\aV2FPT0WU
MZ1-PC M3TITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e0TmlEPTB;Mz62NVYzPCEQvF2= NUnMTIZQW0GQR1XS
OCI-AML2 M2mzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwNkK2O|Eh|ryP Ml7oV2FPT0WU
NCI-H1155 NIrMcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\WXmJZUUN3ME2zMlcxQTR5IN88US=> NGnJTFZUSU6JRWK=
RKO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNwN{exPFkh|ryP MVvTRW5ITVJ?
ECC4 M3fIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPIT2pKSzVyPUOuPVcyQTVizszN M3nmOHNCVkeHUh?=
BB65-RCC NUTXVlhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwOUe1OFch|ryP NUK2O5A5W0GQR1XS
EB-3 NXvaR4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwOUm2N|Mh|ryP NET3dFVUSU6JRWK=
SHP-77 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTWTWM2OD12LkCwOVI1KM7:TR?= MVXTRW5ITVJ?
NCI-H2196 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jWemlEPTB;ND6wOVYzPSEQvF2= NVHLdIZSW0GQR1XS
GI-ME-N NYTJ[pQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjGbVJKSzVyPUSuNFY{QTlizszN NYDVb3U4W0GQR1XS
MN-60 NHzTdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\IflNKSzVyPUSuNVA5PyEQvF2= MlPmV2FPT0WU
NCI-H1694 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\BSFRoUUN3ME20MlE{PDB3IN88US=> NEjoepVUSU6JRWK=
LU-65 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLiTWM2OD12LkG1N|MzKM7:TR?= M{m3bnNCVkeHUh?=
NCI-H1436 NGK3ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMUizN|Mh|ryP MX\TRW5ITVJ?
KINGS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTSZWlnUUN3ME20MlMyPDN{IN88US=> NGLkWlBUSU6JRWK=
GT3TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwM{OyOlgh|ryP NE[3eGZUSU6JRWK=
Becker M1;IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRwM{ezNVIh|ryP MV3TRW5ITVJ?
HCC1187 M2rMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzZTWM2OD12Lki5OlU4KM7:TR?= NFfRTmJUSU6JRWK=
D-502MG MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfFbJVKSzVyPUWuNFA1OTZizszN M3SxfnNCVkeHUh?=
VA-ES-BJ NWL2XJpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TXR2lEPTB;NT6xN|c4QCEQvF2= MmfLV2FPT0WU
NB7 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6eVdZUUN3ME21MlE1OTF{IN88US=> Mn75V2FPT0WU
SW962 NXTYVYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17kXGlEPTB;NT6zPFgyPCEQvF2= M1O1VHNCVkeHUh?=
no-11 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3POcmlEPTB;NT63OlM1OyEQvF2= NU\TdJNvW0GQR1XS
KNS-81-FD NYTp[VB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPtRmJIUUN3ME21MlkxPjl2IN88US=> M3\ncXNCVkeHUh?=
COLO-684 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DQSmlEPTB;NT65PVQ6PCEQvF2= NF3xfZpUSU6JRWK=
D-263MG MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZwMEi4PVUh|ryP MXjTRW5ITVJ?
EW-24 M4j2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS1TWM2OD14LkK4OVEh|ryP MYTTRW5ITVJ?
TE-10 NVr4[G13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvnWZQ5UUN3ME22MlQzPjJ|IN88US=> NUP5Z4lvW0GQR1XS
EKVX MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PI[GlEPTB;Nj60OlMzOSEQvF2= NWnheWVuW0GQR1XS
NCI-H1648 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHlTWM2OD14Lk[3OVU4KM7:TR?= NWXzWVFvW0GQR1XS
LB771-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXiZnlKSzVyPU[uPVI{ODFizszN MoThV2FPT0WU
SK-MEL-1 NFfEPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLjTWM2OD16LkGzNVY3KM7:TR?= NVPvOW9zW0GQR1XS
COLO-668 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTsTWM2OD16LkK3O|g3KM7:TR?= NUjhcWh7W0GQR1XS
EW-12 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[yXVRvUUN3ME24MlQxQDB|IN88US=> MWDTRW5ITVJ?
A253 NITybGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG2RllVUUN3ME24Mlg1PjZzIN88US=> NH21Uo9USU6JRWK=
NCI-H2126 NGf5b2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi4TWM2OD16Lki5N|E6KM7:TR?= MnzKV2FPT0WU
Calu-6 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSySHB1UUN3ME24Mlk6ODR{IN88US=> NVvnXG1GW0GQR1XS
NCI-H23 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nBRWlEPTB;OT6xO|c1PiEQvF2= NEPHOm1USU6JRWK=
WSU-NHL NV24UGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfpcmlnUUN3ME25Mlc4PDd6IN88US=> MljyV2FPT0WU
MMAC-SF MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrQVJN2UUN3ME25Mlk4QTB2IN88US=> MWXTRW5ITVJ?
SK-LMS-1 M{\qSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFyLkK4N|Qh|ryP NFT4cIxUSU6JRWK=
GCIY NVeycVJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\QTWM2OD1zMD61PVI1KM7:TR?= NFfI[llUSU6JRWK=
TE-15 M4HqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpNYhKSzVyPUGxMlYxODRizszN NHH5VY5USU6JRWK=
EoL-1-cell MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PlPGlEPTB;MUGuO|Y5OiEQvF2= NV3GdphXW0GQR1XS
NCI-H2081 M1\vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvmTWM2OD1zMT63O|g3KM7:TR?= NUO0OGw2W0GQR1XS
EW-3 NEPt[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF{LkK0OlMh|ryP MX3TRW5ITVJ?
CAS-1 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{LkO2N|Eh|ryP M{DV[HNCVkeHUh?=
C2BBe1 M3HUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{Lk[xN|Eh|ryP NVq5OIU4W0GQR1XS
D-247MG NIDVPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISycHFKSzVyPUGyMlc6PTJizszN NYPGfVNCW0GQR1XS
NCI-SNU-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLKTWM2OD1zMj64NFE{KM7:TR?= NUi5RY1wW0GQR1XS
LS-1034 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Sc3E2UUN3ME2xOE4{QTd3IN88US=> NUjqNod{W0GQR1XS
EW-18 NFu0O5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jhSmlEPTB;MUSuOFQ5KM7:TR?= NVuzSnJHW0GQR1XS
Raji NUe0V4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OzPWlEPTB;MUSuOVA1QSEQvF2= M4Oz[XNCVkeHUh?=
D-283MED M4[yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF2Lk[yO|Eh|ryP NHyyfZVUSU6JRWK=
MZ2-MEL NVvrSGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwSmJKSzVyPUG0Mlk3QTZizszN M4K5THNCVkeHUh?=
NCI-SNU-16 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf6TJRKSzVyPUG1MlQ3OzNizszN M1\vTnNCVkeHUh?=
P30-OHK MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF5Lke4N|Eh|ryP NUXqNHlPW0GQR1XS
RXF393 M2q2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF7LkCxPFYh|ryP NVrXRWY1W0GQR1XS
NCI-H1395 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPRTWM2OD1{MD62O|A{KM7:TR?= NWHG[JNKW0GQR1XS
U-698-M M2PBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\meVFKSzVyPUKwMlcxPzVizszN NF3HVWRUSU6JRWK=
NCI-SNU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj0VnFKUUN3ME2yNE44OjJ|IN88US=> M13XOHNCVkeHUh?=
SW684 NUDSNFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHPN4M4UUN3ME2yNU4yPzF4IN88US=> Moj0V2FPT0WU
NCI-H716 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vafGlEPTB;MkGuN|E2PCEQvF2= MkHxV2FPT0WU
JVM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlTWM2OD1{MT60NVM{KM7:TR?= MV;TRW5ITVJ?
NCI-H1581 M2myS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXmTWM2OD1{Mj60NVQ5KM7:TR?= M3Oxe3NCVkeHUh?=
CA46 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZTWM2OD1|MT62PVM3KM7:TR?= NH7pN|dUSU6JRWK=
SNB75 NGPRTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfYeGhKSzVyPUOzMlY2ODNizszN MmPaV2FPT0WU
KNS-42 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN3Lkm2NlQh|ryP MXzTRW5ITVJ?
TUR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7sOYJkUUN3ME2zOk4xPTJzIN88US=> MoTaV2FPT0WU
REH NGnxcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTN5LkiyNVEh|ryP M2LGO3NCVkeHUh?=
EW-22 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTR{LkK4PFUh|ryP NGHLZodUSU6JRWK=
NCI-H446 NXXaXVBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK2TWM2OD12Mj63PFU{KM7:TR?= MXzTRW5ITVJ?
ES3 NFH1SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDCOJFKSzVyPUSzMlE{OzlizszN NV7uSpNVW0GQR1XS
EW-11 M1:4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LReGlEPTB;NESuPFIyQCEQvF2= NUjSWXNPW0GQR1XS
RH-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle1TWM2OD12Nz61PFEzKM7:TR?= M1\MUHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID